Greetings from Young-Bae Kim,
Chairman of DuChemBio Co., Ltd.
"Last to enter, now one and only in Korea"
DCB has grown to be a leading Radiopharmaceutical company in Korea for 10 years despite its late entry to the market. With forward-looking investments in new drug development and manufacturing technology, DCB now has a larger new drug pipeline and better export performance than its domestic competitors.
Internationally, DCB has already entered The Philippine market as a commercially unique company showing great performance. Now, it is planning to advance into other East Asian markets with its rich portfolio of established and new Radiopharmaceuticals for diagnosis and treatment.
From my successful experience in the pharmaceutical market for the past 50 years, I am convinced that DCB has a full potential to become one of the world leaders in the global Radiopharmaceutical industry. Firmly based on its continued investments in R&D and radio-pharmacy networks, DCB promises to show a sustainable growth as a leading biotech company in Korea and the Asia-Pacific region.
Young-Bae Kim, Chairman of DuChemBio Co., Ltd.